SCIENTIFIC AND INFORMATION-ANALYTICAL MAGAZINE

ISSN 1024-6177 (Print), ISSN 2618-9615 (Online)

JOURNAL DESCRIPTION

The Medical Radiology and Radiation Safety journal ISSN 1024-6177 was founded in January 1956 (before December 30, 1993 it was entitled Medical Radiology, ISSN 0025-8334). In 2018, the journal received Online ISSN: 2618-9615 and was registered as an electronic online publication in Roskomnadzor on March 29, 2018. It publishes original research articles which cover questions of radiobiology, radiation medicine, radiation safety, radiation therapy, nuclear medicine and scientific reviews. In general the journal has more than 30 headings and it is of interest for specialists working in thefields of medicine¸ radiation biology, epidemiology, medical physics and technology. Since July 01, 2008 the journal has been published by State Research Center - Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency. The founder from 1956 to the present time is the Ministry of Health of the Russian Federation, and from 2008 to the present time is the Federal Medical Biological Agency.

Members of the editorial board are scientists specializing in the field of radiation biology and medicine, radiation protection, radiation epidemiology, radiation oncology, radiation diagnostics and therapy, nuclear medicine and medical physics. The editorial board consists of academicians (members of the Russian Academy of Science (RAS)), the full member of Academy of Medical Sciences of the Republic of Armenia, corresponding members of the RAS, Doctors of Medicine, professor, candidates and doctors of biological, physical mathematics and engineering sciences. The editorial board is constantly replenished by experts who work in the CIS and foreign countries.

Six issues of the journal are published per year, the volume is 13.5 conventional printed sheets, 88 printer’s sheets, 1.000 copies. The journal has an identical full-text electronic version, which, simultaneously with the printed version and color drawings, is posted on the sites of the Scientific Electronic Library (SEL) and the journal's website. The journal is distributed through the Rospechat Agency under the contract № 7407 of June 16, 2006, through individual buyers and commercial structures. The publication of articles is free.

The journal is included in the List of Russian Reviewed Scientific Journals of the Higher Attestation Commission. Since 2008 the journal has been available on the Internet and indexed in the RISC database which is placed on Web of Science. Since February 2nd, 2018, the journal "Medical Radiology and Radiation Safety" has been indexed in the SCOPUS abstract and citation database.

Brief electronic versions of the Journal have been publicly available since 2005 on the website of the Medical Radiology and Radiation Safety Journal: http://www.medradiol.ru. Since 2011, all issues of the journal as a whole are publicly available, and since 2016 - full-text versions of scientific articles. Since 2005, subscribers can purchase full versions of other articles of any issue only through the National Electronic Library. The editor of the Medical Radiology and Radiation Safety Journal in accordance with the National Electronic Library agreement has been providing the Library with all its production since 2005 until now.

The main working language of the journal is Russian, an additional language is English, which is used to write titles of articles, information about authors, annotations, key words, a list of literature.

Since 2017 the journal Medical Radiology and Radiation Safety has switched to digital identification of publications, assigning to each article the identifier of the digital object (DOI), which greatly accelerated the search for the location of the article on the Internet. In future it is planned to publish the English-language version of the journal Medical Radiology and Radiation Safety for its development. In order to obtain information about the publication activity of the journal in March 2015, a counter of readers' references to the materials posted on the site from 2005 to the present which is placed on the journal's website. During 2015 - 2016 years on average there were no more than 100-170 handlings per day. Publication of a number of articles, as well as electronic versions of profile monographs and collections in the public domain, dramatically increased the number of handlings to the journal's website to 500 - 800 per day, and the total number of visits to the site at the end of 2017 was more than 230.000.

The two-year impact factor of RISC, according to data for 2017, was 0.439, taking into account citation from all sources - 0.570, and the five-year impact factor of RISC - 0.352.

Медицинская радиология и радиационная безопасность, 2014. Том 59. № 6. С. 54-62

ЯДЕРНАЯ МЕДИЦИНА

В.В. Крылов, Т.Ю. Кочетова

РАДИОНУКЛИДНАЯ ТЕРАПИЯ 188Re-ГИДРОКСИЭТИЛИДЕНДИФОСФОНАТОМ В ЛЕЧЕНИИ БОЛЬНЫХ С МЕТАСТАЗАМИ В КОСТИ

МРНЦ им. А.Ф. Цыба – филиал ФГБУ «ФМИЦ им. П.А.Герцена» Минздрава России. E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

РЕФЕРАТ

Одним из эффективных методов лечения обширной группы тяжелых пациентов с множественными метастазами различных опухолей в кости и болевым синдромом является радионуклидная терапия (РНТ). 188Re-HEDP — один из эффективных, безопасных и удобных в клиническом применении остеотропных радиофармпрепаратов (РФП). Накоплен обширный опыт применения этого препарата в мировой клинической практике, в России завершены клинические испытания отечественного аналога 188Re-КЭДФ. Многочисленные исследования подтвердили безопасность применения 188Re-HEDP (КЭДФ) в терапевтической дозировке 2,6–3,3 ГБк. Гематологическая токсичность является основным побочным эффектом и проявляется в виде обратимой тромбоцитопении и лейкопении I–II степени через 3–5 нед после введения препарата. Эффективность 188Re-HEDP (КЭДФ) не уступает другим остеотропным РФП и достигает 80 %. В проспективном рандомизированном исследовании повторных введений 188Re-HEDP с интервалом в 8 нед при раке предстательной железы с метастазами в кости было показано увеличение эффективности с 60 до 90 %, а также выявлено увеличение продолжительности жизни пациентов с 7,0 мес при однократном введении РФП, до 12,7 мес при двукратном. Противоопухолевый эффект заключался в снижении уровня ПСА на 50 % длительностью более 8 нед у 39 % пациентов после двукратного введения и только у 7 % после однократного, уменьшение количества очагов по данным остеосцинтиграфии чаще наблюдалось после двукратного введения 188Re-HEDP. Разрабатываются схемы комплексного лечения больных с метастазами в кости, в частности, показана целесообразность сочетания РНТ с бисфосфонатами, разработаны схемы безопасного последовательного сочетания химиотерапии и 188Re-HEDP.

Ключевые слова: метастазы в кости, радионуклидная терапия, рений-188 ОЭДФ болевой синдром, паллиативная терапия

СПИСОК ЛИТЕРАТУРЫ

  1. Крылов В.В., Цыб А.Ф., Дроздовский Б.Я. Радионуклидная терапия у больных с метастатическими поражениями костей. // Медицинская радиология и радиационная безопасность, 2006. Т. 51. № 3. С. 65–74.
  2. Цыб А.Ф., Крылов В.В., Дроздовский Б.Я. и соавт. Радионуклидная терапия самарием оксабифором, Sm-153 при раке молочной и предстательной железы с метастазами в кости. // Сиб. онкол. журнал, 2006. № 3. С. 8–17.
  3. Крылов В.В., Цыб А.Ф., Дроздовский Б.Я. Радионуклидная терапия в паллиативном лечении больных с метастазами в кости. // Паллиативная медицина и реабилитация, 2005. № 3. С. 40–47.
  4. Silberstein E.B., Taylor A.T. Jr. EANM procedure guidelines for treatment of refractory metastatic bone pain. // Eur. J. Nucl. Med. Mol Imaging, 2003, vol. 30, no. 3, pp. 7–11.
  5. Lin W.Y., Lin C.P., Yeh S.J. et al. Rhenium-188 hydroxyethylidene diphosphonate: a new generator-produced radiotherapeutic drug of potential value for the treatment of bone metastases. // Eur. J. Nucl. Med., 1997, vol. 24, no. 6, pp. 590–595.
  6. Петриев В.М., Сморызанова О.А., Скворцов В.Г. Изучение фармакокинетики 188Rе-КNА-гидро­кси­этилидендифосфоната в организме интактных крыс. // Вопросы биол., мед. и фарм. химии, 2007. № 2. С.11–16.
  7. Maxon H.R. 3rd, Schroder L.E., Washburn L.C. et al. Rhenium-188(Sn)HEDP for treatment of osseous metastases. // J. Nucl. Med., 1998, vol. 39, no. 4, pp. 659–663.
  8. Knapp F.F. Jr, Beets A.L., Guhlke S. et al. Availability of rhenium-188 from the alumina-based Tungsten-188/Rhenium-188 generator for preparation of Rhenium-188-labeled radiopharmaceuticals for cancer treatment. // Anticancer Res., 1997, vol. 17, no. 3B, pp. 1783–1795.
  9. Hsieh B.T., Hsieh J.F., Tsai S.C. et al. Comparison of various Rhenium-188-labeled diphosphonates for the treatment of bone metastases. // Nucl. Med. Biol., 1999, vol. 26, no. 8, pp. 973–976.
  10. Róka R., Séra T., Pajor L. et al. Clinical experience with Rhenium-188 HEDP therapy for metastatic bone pain. // Orv. Hetil, 2000, vol. 141, suppl. 7, no. 19, pp. 1019–1023.
  11. Liepe K., Hliscs R., Kropp J. et al. Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases. // J. Nucl. Med., 2003, vol. 44, no. 6, pp. 953–960.
  12. Smolyarchuk M., Davydov G., Aleksandrova A. et al. Evaluation of the pharmacokinetics of 188Re-HEDP and 99mTc-HDP in humans. // World J. Nucl. Med., 2013, vol. 12, suppl. 2, pp. 228–229.
  13. Palmedo H., Guhlke S., Bender H. et al. Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases. // Eur. J. Nucl. Med., 2000, vol. 27, no. 2, pp. 123–130.
  14. Li S., Liu J., Zhang H. et al. Rhenium-188 HEDP to treat painful bone metastases. // Clin. Nucl. Med., 2001, vol. 26, no. 11, pp. 919–922.
  15. Cheng A., Chen S., Zhang Y. et al. The tolerance and therapeutic efficacy of Rhenium-188 hydroxyethylidene diphosphonate in advanced cancer patients with painful osseous metastases. // Cancer Biother. Radiopharm., 2011, vol. 26, no. 2, pp. 237–244.
  16. Liepe K., Kropp J., Runge R., Kotzerke J. Therapeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases. // Brit. J. Cancer, 2003, vol. 89, suppl. 18, no. 4, pp. 625–629.
  17. Zhang H., Tian M., Li S. et al. Rhenium-188-HEDP therapy for the palliation of pain due to osseous metastases in lung cancer patients. // Cancer Biother. Radiopharm., 2003, vol. 18, no. 5, pp. 719–726.
  18. Krylov V., Kochetova T., Smolyarchuk M. et al. Evaluation of 188Re-KHEDP (Phosphoren) for palliative treatment in patients with bone metastases. // World J. Nucl. Med., 2013, vol. 12, suppl. 2, pp. 255–256.
  19. Liepe K., Kotzerke J. A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases. // Nucl. Med. Commun., 2007, vol. 28, no. 8, pp. 623–630.
  20. Palmedo H., Manka-Waluch A., Albers P. et al. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate. // J. Clin. Oncol., 2003, vol. 21, suppl. 1, no. 15, pp. 2869–2875.
  21. Biersack H.J., Palmedo H., Andris A. et al. Palliation and survival after repeated 188Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: a retrospective analysis. // J. Nucl. Med., 2011, vol. 52, no. 11, pp. 1721–1726.
  22. Krylov V., Gulidov I., Ivanova I. et al. 153Sm-oxabiphore radionuclide therapy combined with external beam radiation therapy (8Gy) in breast cancer patients with bone metastases. // World J. Nucl. Med., 2009, vol. 8, no. 4, pp. 240.
  23. Rasulova N., Lyubshin V., Arybzhanov D. et al. Optimal timing of bisphosphonate administration in combination with samarium-153 oxabifore in the treatment of painful metastatic bone disease. // World J. Nucl. Med., 2013, vol. 12, no. 1, pp. 14–18.
  24. Tu S.M., Delpassand E.S., Jones D. et al. Strontium-89 combined with doxorubicin in the treatment of patients with androgen-independent prostate cancer. // Urol. Oncol., 1996, vol. 2, no. 6, pp. 191–197.
  25. Sciuto R., Festa A., Rea S. et al. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. // J. Nucl. Med., 2002, vol. 43, no. 1, pp. 79–86.
  26. Pagliaro L.C., Delpassand E.S., Williams D. et al. A phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases. // Cancer, 2003, vol. 97, suppl. 15, no. 12, pp. 2988–2994.
  27. Ricci S., Boni G., Pastina I. et al. Clinical benefit of bone-targeted radiometabolic therapy with
    153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer. // Eur. J. Nucl. Med. Mol. Imaging, 2007, vol. 34, no. 7, pp. 1023–1030.
  28. Lam M.G., Bosma T.B., van Rijk P.P., Zonnenberg B.A. 188Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study. // Eur. J. Nucl. Med. Mol. Imaging, 2009, vol. 36, no. 9, pp. 1425–1433.
  29. van Dodewaard-de Jong J.M., de Klerk J.M., Bloemendal H.J. et al. A phase I study of combined docetaxel and repeated high activity 186Re-HEDP in castration-resistant prostate cancer (CRPC) metastatic to bone (the TAXIUM trial). // Eur. J. Nucl. Med. Mol. Imaging, 2011, vol. 38, no. 11, pp. 1990–1998.

Contact Information

 

46, Zhivopisnaya st., 123098, Moscow, Russia Phone: +7 (499) 190-95-51. E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Journal location

Attendance

4007628
Today
Yesterday
This week
Last week
This month
Last month
For all time
2220
6045
21261
30856
137334
124261
4007628
Forecast today
8760

Your IP:216.73.217.31
Visitor Counter

© Журнал "Медицинская радиология и радиационная безопасность" 2020г.

Яндекс.Метрика

Наверх